ID: ALA242020

Max Phase: Preclinical

Molecular Formula: C29H26N2O10

Molecular Weight: 562.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(CNC(=O)c2cc(=O)c3c(O)cc(OCCc4ccc(NC(=O)C(=O)O)c(OC)c4)cc3o2)cc1

Standard InChI:  InChI=1S/C29H26N2O10/c1-38-18-6-3-17(4-7-18)15-30-27(34)25-14-22(33)26-21(32)12-19(13-24(26)41-25)40-10-9-16-5-8-20(23(11-16)39-2)31-28(35)29(36)37/h3-8,11-14,32H,9-10,15H2,1-2H3,(H,30,34)(H,31,35)(H,36,37)

Standard InChI Key:  MLDHFNNJFGENAK-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 562.53

Molecular Weight (Monoisotopic): 562.1587

AlogP: 3.09

#Rotatable Bonds: 10

Polar Surface Area: 173.63

Molecular Species: ACID

HBA: 9

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 12

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 2.54

CX Basic pKa:

CX LogP: 3.52

CX LogD: -0.31

Aromatic Rings: 4

Heavy Atoms: 41

QED Weighted: 0.21

Np Likeness Score: -0.41

References

1. Choi SR, Pradhan A, Hammond NL, Chittiboyina AG, Tekwani BL, Avery MA..  (2007)  Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors.,  50  (16): [PMID:17636950] [10.1021/jm070336k]

2. Dragovich PS, Fauber BP, Corson LB, Ding CZ, Eigenbrot C, Ge H, Giannetti AM, Hunsaker T, Labadie S, Liu Y, Malek S, Pan B, Peterson D, Pitts K, Purkey HE, Sideris S, Ultsch M, VanderPorten E, Wei B, Xu Q, Yen I, Yue Q, Zhang H, Zhang X..  (2013)  Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase.,  23  (11): [PMID:23628333] [10.1016/j.bmcl.2013.04.001]

Source

Source(1):

• Scientific Literature